...
首页> 外文期刊>International Journal of Pharmaceutics >A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery
【24h】

A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery

机译:一种新型的乳铁蛋白修饰的β-环糊精纳米载体,用于靶向脑的药物递送

获取原文
获取原文并翻译 | 示例
           

摘要

The blood-brain barrier (BBB) restricts the transfer and delivery of most drug substances to brain. In this study, a novel nano-drug delivery system for brain-targeting was developed and investigated in vitro and in vivo. Lactoferrin (Lf) was selected as a brain-targeting ligand and conjugated to β-cyclodextrin (β-CD) via the heterobifunctional polyethyleneglycol (PEG) linker NHS-PEG-MAL, yielding Lf conjugated β-cyclodextrin (Lf-CD). UV-vis, FTIR, NMR and transmission electron microscopy (TEM) techniques clearly demonstrated the successful synthesis of Lf-CD nanoparticles with the average diameter of 92.9 ± 16.5 nm. Using near-infrared fluorescent dye IR-775 chloride (IR) as a model compound of poorly water-soluble drugs, IR-loaded Lf-CD nanoparticles (Lf-CD/IR) were successfully prepared with a high entrapment efficiency of 98.1 ± 4.8%. Biodistribution and pharmacokinetics of Lf-CD/IR were evaluated in KM mice after intravenous administration. The results of tissue distribution studies revealed that Lf-CD/IR treatment showed greatly improved BBB transport efficiency. In addition, AUC0-2 h of IR in brain after Lf-CD/IR treatment was seven fold higher compared with that of IR treatment without Lf-CD nano-carriers, demonstrating that the introduction of Lf-CD drug-delivery system positively resulted in a higher AUC located in brain tissue. These results provide evidence that Lf-CD nanoparticles could be exploited as a potential brain-targeting drug delivery system for hydrophobic drugs and diagnostic reagents which normally fail to pass through the BBB.
机译:血脑屏障(BBB)限制了大多数药物向大脑的转移和传递。在这项研究中,开发了一种新型的脑靶向纳米药物输送系统,并在体内和体外进行了研究。选择乳铁蛋白(Lf)作为脑靶向配体,并通过异双功能聚乙二醇(PEG)接头NHS-PEG-MAL与β-环糊精(β-CD)偶联,得到Lf与β-环糊精(Lf-CD)偶联。 UV-vis,FTIR,NMR和透射电子显微镜(TEM)技术清楚地证明了成功合成的Lf-CD纳米粒子的平均直径为92.9±16.5 nm。使用近红外荧光染料IR-775氯化物(IR)作为水溶性差的药物的模型化合物,成功制备了载有IR的Lf-CD纳米颗粒(Lf-CD / IR),具有98.1±4.8的高包封率%。静脉给药后,在KM小鼠中评估了Lf-CD / IR的生物分布和药代动力学。组织分布研究的结果表明,Lf-CD / IR治疗显示BBB转运效率大大提高。此外,与不使用Lf-CD纳米载体的IR治疗相比,Lf-CD / IR治疗后的大脑IR IR的AUC0-2 h高出七倍,表明引入Lf-CD药物递送系统是积极的位于大脑组织中较高的AUC中。这些结果提供了证据,即Lf-CD纳米颗粒可以用作疏水性药物和诊断试剂的潜在的脑靶向药物递送系统,这些药物通常无法通过BBB。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号